Exercise, Urban Food Production, Preparation and Consumption: Implications, Benefits and Risks to Grow-Your-Own (GYO) Gardeners

This study is the first to consider, and estimate, the influence of gardening routines on exposures to both health benefits and health risks. This holistic approach helped to contrast the healthy lifestyle of gardening with health risks from exposures to potentially toxic elements such as Cd and Pb in urban environments. A total of 120 participants who grew their own produce in an urban setting were recruited to the study. A detailed questionnaire was developed that included sections on gardening activity, cultivation and consumption of produce, consumption of commercially grown produce, and other lifestyle factors. Administered alongside the questionnaire was the Short Form 36 (v2) as a standardised tool for measuring physical and mental health. Fruit and vegetable consumption was found to be correlated with the amount of gardening individuals did in autumn/winter and was greater than fruit and vegetable consumption, on average, in the UK general population. Levels of physical activity were also found to be higher in our study than regional averages, whilst BMI was lower than average. This is the first study to find a relationship between gardening more regularly (in autumn/winter) and the physical component of the Short Form 36, and this relationship was elevated compared to non-gardening populations. The physical component scores from this study were also significantly higher for older participants, compared to means from a Western population. This finding supports studies suggesting that gardening may be more beneficial for the elderly generation. These benefits were assessed in the context of potential exposures estimated from the type and frequency of produce being consumed. The benefit of maintaining a healthy lifestyle is likely to outweigh the health risks of gardening on soils mildly contaminated with Cd and Pb but requires formal consideration within a risk management framework.

ATTENTION DEFICIT HYPERACTIVITY DISORDER SYMPTOMS IN ADULTS WITH ESSENTIAL TREMOR

Background: Essential tremor is the most common movement disorder. İn this disease, which is characterized by tremor that increases with action and passes at rest, different accompanying symptoms can also be seen. Objective: The purpose of this study was to investigate attention deficit hyperactivity symptoms in adults with ET. Methods: Fifty six essential tremor patients and 56 controls were included in the study. Patients were recruited from outpatient clinic at Kirikkale University Medicine Faculty. An informed consent form was signed by each patient after detailed information. Institutional ethics committee approval was obtained. Patients’ characteristics such as education level, gender, age and disease duration were recorded. Symptoms of ADHD in patients and controls were determined by using the Adult Report Deficit / Hyperactivity Disorder Self Report Scale. Short Form-36 and Hospital Anxiety and Depression Scale were also performed. Essential tremor severity was determined by using the Whiget essential tremor scale. Results: Essential tremor patients had significantly higher rate of Adult Attention Disorder Self-Report Scale Deficit/Hyperactivity scores compared to controls. Scores of Adult Attention Deficit/Hyperactivity Disorder Self-Report Scale were associated with depression and anxiety scores and physical and mental component scores of Short Form-36 in bivariate analyses. There was a positive correlation between tremor severity and ASRS scores( ASRS A scores= 17,3±5,5, p=0,032, ASRS B scores= 27,7±6,7,p=0,043, ASRS T scores= 45±12,2, p=0,017) however there was no significant statistical relationship between the duration of disease and ASRS scores. Conclusion: This study showed that ADHD symptoms can be observed in adult essential tremor patients and this may be associated with increased psychosocial morbidity and lowered quality of life in ET patients.

Chronic Liver Disease Lowering Physical and Mental Health Dimensions

The most prevalent diseases within the world related to major illness and mortality are chronic liver diseases. The developing pervasiveness of chronic liver disease has resulted in increased interest in health-related quality of life, which incorporates the physical well-being of a patient and his emotional and social well-being. This study aimed to define the quality of life of patients with chronic liver disease. This study used the Quality-of-Life Short Form 36 Indonesian version to examine 102 patients with chronic liver disease from two hospitals with a descriptive design. The quality of life of the patients was comparatively low (M ± SD: physical, 42.4 ± 18.33; mental, 48.44 ± 17.19). On both the physical and mental health dimensions of quality of life, the patients in this study scored less than 50 on a scale of 0 to 100, with low scores indicating the low quality of life both physically and mentally. Improving quality of life necessitates a multidisciplinary strategy that combines physical and mental health screening and management. Surrounding support will encourage adaptive coping mechanisms to manage the illness for improving quality of life. AbstrakPenyakit Hati Kronis Menurunkan Dimensi Kesehatan Fisik dan Mental. Penyakit yang paling umum di dunia yang berhubungan dengan penyakit utama dan kematian adalah penyakit hati kronis. Penyebaran penyakit hati kronis yang berkembang telah menghasilkan peningkatan minat pada kualitas hidup yang berhubungan dengan kesehatan, yang mencakup kesejahteraan fisik pasien dan kesejahteraan emosional dan sosialnya. Tujuan dari penelitian ini adalah untuk menjabarkan kualitas hidup pasien penyakit hati kronis. Penelitian ini menggunakan Quality-of-Life Short Form 36 versi Bahasa Indonesia untuk mengumpulkan data dari 102 pasien dari dua rumah sakit melalui desain deskriptif. Penelitian ini menunjukkan bahwa kualitas hidup pasien relatif rendah (M ± SD: fisik, 42,4 ± 18,33; mental, 48,44 ± 17,19). Pada kedua dimensi kualitas hidup yaitu kesehatan fisik dan mental, pasien dalam penelitian ini mendapat nilai kurang dari 50 pada skala 0 hingga 100, dengan nilai rendah menunjukkan kualitas hidup rendah baik fisik maupun mental. Peningkatkan kualitas hidup pasien memerlukan strategi multidisiplin yang menggabungkan skrining dan manajemen kesehatan fisik dan mental. Dukungan lingkungan akan mendorong mekanisme koping yang adaptif untuk mengelola penyakit dalam meningkatkan kualitas hidup.Kata Kunci: Indonesia, kualitas hidup, penyakit hati kronis, sirosis

Estimating the minimal clinically important difference for the Physical Component Summary of the Short Form 36 for patients with stroke

Objective To determine the Physical Component Summary (PCS) score's minimal clinically important difference (MCID) on the Short Form 36 (SF-36) for people with stroke. Methods We conducted secondary analysis of data from a large randomized controlled trial (N = 400) in the post-hospital discharge phase of stroke rehabilitation with outcome measurement 6 and 12 months following stroke. Three methods were used for estimating the MCID: two anchor and one distribution. Method 1 compared SF-36 PCS scores at 12 months for responses to the SF-36’s Perceived Health Change (PHC) question. Method 2 compared the change in PCS score between 6 and 12 months for responses to the PHC question. Method 3 used Cohen’s method to estimate the MCID from the PCS score distribution. Results Method 1: the mean PCS score increased by 3.0 units (95% confidence interval [CI] 2.2–3.9) for each unit change in the PHC question. Method 2: the mean change in PCS score increased by 2.1 units (95% CI 1.4–2.8) for each unit change in the PHC question. Method 3: the MCID was estimated to be 1.8 units. Conclusions Our estimate of the MCID for the PCS in patients with stroke was 1.8 to 3.0 units.

Qualidade de vida de pacientes acometidos por acidente vascular cerebral

O Acidente Vascular Cerebral (AVC) é uma doença grave, suas sequelas podem comprometer a qualidade de vida das pessoas acometidas. Objetivo: Analisar a qualidade de vida de pacientes acometidos por AVC. Metodologia: Trata-se de um estudo descritivo, exploratório do tipo transversal, com amostra composta por pacientes acometidos por AVC de ambos os sexos, com idade acima de 21 anos. Foram aplicados os questionários: Mini-Exame do estado mental (MEEM), Sociodemográfico e o Medical Outcomes Short-Form 36-item Health Survey (SF-36). Resultados: 20 pacientes estavam em atendimento, desses apenas 15 atingiram a pontuação necessária no MEEM para entrar na pesquisa. 9 (60,0%) eram do sexo masculino e 6 (40,0%) do sexo feminino, com idade igual ou superior a 60 anos, com faixas etárias de 60 a 69 anos 6 (40,0%) e 71 a 79 anos 2 (13,3%), em relação à raça, a branca e a parda se igualaram com 7 (46,7%), ao tipo de AVC observou-se que 11 (73,3%) dos pacientes sofreram AVC Isquêmico e 4 (26,7%) AVC Hemorrágico. Sobre o tempo de ocorrido do AVC, 12 (80%) tinham tido há mais de 1 ano. Foram observados baixos escores em todos os domínios da SF-36, principalmente nos aspectos físicos (26,66), capacidade funcional (43,33), e aspectos emocionais (41,93). Conclusão: Foi observado o comprometimento na percepção da Qualidade de Vida (QV) com valores baixos de todos os domínios, principalmente nos aspectos físicos, emocionais e capacidade funcional, com maior frequência em pacientes com diagnóstico clínico de AVC do tipo isquêmico, com igual ou superior a 60 anos de gênero masculino

[ID 54403] DESENVOLVIMENTO E APLICAÇÃO DE UM PROTOCOLO FISIOTERAPÊUTICO EM PACIENTES COM MASTALGIA

Objetivo: Verificar a influência do protocolo fisioterapêutico, composto por eletroterapia e exercício físico em mulheres com mastalgia. Metodologia: Trata-se de um estudo clínico não-controlado com amostra intencional de dez mulheres com mastalgia, aprovado pelo Comitê de Ética em Pesquisa (CEP) e realizado no Centro de Atenção a Saúde da Mulher e da Criança (CASMUC) da Universidade Federal do Pará (UFPA). Os instrumentos avaliativos aplicados antes e após o protocolo terapêutico foram à versão brasileira do Questionário de Qualidade de Vida Short Form-36 (SF-36) e Escala Visual Analógica (EVA), analisados pelo teste t Student, e Escala Medical Research Council (MRC), analisado pelo teste de Wilcoxon. O protocolo da pesquisa consistiu nas pacientes serem submetidas às sessões terapêuticas, duas vezes semanais, totalizando dez sessões. As condutas foram compostas pela utilização da neuroestimulação elétrica transcutânea (TENS) associado ao exercício físico. Resultados: Ocorreu redução significativa da dor na mama direita (p=0,0117*) e esquerda (p=0,0464*), pela EVA, melhora significativa na análise individual dos domínios de qualidade de vida relacionada à dor (p=0,0380*) e saúde mental (p=0,0015*) pelo SF-36 e melhora relativa da força muscular pelo MRC. Conclusão: O protocolo fisioterapêutico demonstrou eficácia frente ao quadro álgico das participantes, assim como resultados positivos na qualidade de vida e força muscular.

ОСОБЛИВОСТІ ЯКОСТІ ЖИТТЯ КАРДІОХІРУРГІЧНИХ ПАЦІЄНТІВ, ЯКИМ ВИКОНАНО МІНІ-ІНВАЗИВНІ ДОСТУПИ

Мета: визначити доцільність та ефективність проведення протезування аортального клапана з міні-доступу на основі аналізу якості життя пацієнтів через 12 місяців після операції. Матеріали і методи. Опитали 50 хворих, яким виконано протезування аортального клапана у 2019 р. Усіх пацієнтів поділено на 2 групи. У 1-й групі – 25 осіб (20 чоловіків (80 %) та 5 жінок (10 %)) – протезування виконували із поздовжньої серединної стернотомії (ПСС), у 2-й групі – 25 осіб (20 чоловіків (80 %) та 5 жінок (10 %)) – з міні J-подібної стернотомії (МІД). Якість життя оцінювали через 12 місяців після операції за допомогою опитувальника Medical Outcomes Study Short Form 36 (MOS SF-36). Результати. У 25 хворих, яким оперативне втручання проведено через J-подібну міні-інвазивну стернотомію, виявлено статистично значущу зміну оцінки якості життя при аналізі стану психологічного здоров’я ((73,6±1,71) %) порівняно з ПСС ((66,51±1,40) %) (р<0,05). Це говорить про поліпшення якості життя хворих даної групи. У групі з МІД, порівняно з ПСС, ми спостерігали тенденцію до кращих показників фізичного функціонування – (83,60±2,05) % проти (79,80±2,23) %; рольового функціонування, зумовленого фізичним станом, – (74,00±4,45) % проти (68,00±3,67) %; інтенсивності болю – (92,80±3,36) % проти (85,28±2,97) %; загального стану здоров’я – (64,04±2,67) % проти (61,68±3,08) %; життєвої активності – (75,20±2,10) % проти (72,30±1,65) %; соціального функціонування – (90,00±4,01) % проти (83,83±2,50) %; рольового функціонування, зумовленого емоційним ста­ном, – (84,01±5,22) % проти (79,14±3,90) %. Висновки. Пацієнти з міні-інвазивним доступом мають статистично краще психічне здоров’я після втручання, ніж пацієнти із серединною стернотомією. Як результат, у цих пацієнтів менший ризик розвитку депресії, тривоги, переживань, психічних розладів. Інші показники мали тенденцію до вищих результатів при МІД порівняно з ПСС.

AB0869-HPR HOW TO IMPROVE THE QUALITY-OF-LIFE IN PATIENTS WITH OSTEOPOROSIS?

Background:This paper is an assessment of quality-of-life for patients living with osteoporosis. It employs special questionnaires and scales to allow for more detailed observation of the patient both during initial treatment and in dynamics. This allows us to establish the effectiveness of the therapy, to assess the need to correct the treatment and rehabilitation program, and to compare the effectiveness of various treatment methods and determine disease prognosis.Objectives:to assess quality-of-life in patients with osteoporosis for further development of treatment and rehabilitation programs.Methods:To assess the quality-of-life in patients with osteoporosis, HRQOL and SF-36 scale were used. The study was conducted from January to December 2019, at the Republican Clinical Hospital of the Chuvash Republic. The study involved 70 patients (n = 70) with a diagnosis of osteoporosis with a pathological fracture. Of the 70 patients included in the study, 35 women aged 67 ± 1.2 years and 35 men aged 60 ± 1.2 years. The results were statistically processed using MS Office Excel programs.Results:According to the analysis carried out by the HRQOL method, more than half of the patients (52.13%) experienced daily back pain, which worsens their mood and well-being. When assessing the degree of pain, almost half of the patients (48.73%) rated their pain by VAS as moderate. Moreover, most of the respondents experienced a “significant” (46.51%) or “moderate” (34.29%) decrease in social activity due to pain syndrome associated with osteoporosis. In connection with this, 44.51% rated their satisfaction with their lives as “average degree of satisfaction”.When analyzing the quality-of-life indicators according to the SF-36 scales, we determined that the mental component of health predominates for women (The Short Form-36: MH=68,6±3,45 (Men: MH=48,5±2,85)). In men, high quantitative values of the scales “physical” and “role physical functioning” (The Short Form-36: PF=62,5±3,33; RP=58,4±3,81) indicate a more pronounced nature of changes in somatic status, which has a significant impact on the quality-of-life. The intensity of pain was perceived to be higher by men (The Short Form-36: BP=75,6±4,06) than by women (The Short Form-36: BP=35,7±1,86). This confirms that osteoporosis and its complications negatively affect the human psyche and can significantly worsen the quality-of-life.Conclusion:Analysis of quality-of-life indicators using the SF-36, HRQOL method contributes to a more correct choice of effective strategy for specialized medical care and rehabilitation for patients with osteoporosis. This choice should be developed individually, taking into account the age, gender characteristics, the severity of structural and functional disorders and the psychological state of the patient. It must also take into account the presence and severity of concomitant diseases, which will require additional research and discussion at different levels of the organization of medical care.Disclosure of Interests:None declared

AB0893-HPR TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES, AND CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): TURKISH COHORT RESULTS OF THE SENSE STUDY

Background:Suboptimal control of RA may lead to severe and progressive articular damage, loss of function, and deterioration of the quality of life (QoL).Objectives:To assess treatment satisfaction, sociodemographic, clinical, health care resource utilization, and QoL characteristics of patients with sub-optimally controlled RA and treated with conventional synthetic and/or biologic DMARDs.Methods:This study was an international, multicenter, cross-sectional, non-interventional study. Adult RA patients with moderate to severe disease activity (DAS28>3.2) were enrolled. Patient satisfaction was evaluated with Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4) with a scale ranging from 0 (indicating poor satisfaction) to 100 (indicating perfect satisfaction). Patients were questioned regarding treatment adherence, patient preferences, and expectations. Workability was evaluated using Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA, version 2.0). Short Form 36 (V2) survey were performed to all patients.Results:One hundred sixty-four patients were included in the study and most (78.0%) were female. The median age was 57.0 years, ranging between 22.0 and 84.0 years. Half of the patients (50.6%) were primary school graduates and 6.1% were unemployed due to RA and seeking work. Median time since RA diagnosis was 8.0 years and mean (±SD) DAS28-CRP score was 4.8 (±1.0). Mean total activity impairment was 54.9% (±27.4). In the past 3 months from enrollment, the mean number of healthcare professional and emergency room visits were 1.8 (±1.1) and 1.8 (±1.3), respectively. Mean number and length of hospitalizations in the previous 3 months were 1.1 (±0.3) times and 8.3 (±7.2) days, respectively. Mean TSQM scores were 53.5 (±21.4) for effectiveness, 86.0 (±26.7) for side effects, 67.8 (±16.5) for convenience, and 57.7 (±22.0) for global satisfaction. The leading expectation was ‘lasting relief of RA symptoms’ (mean score: 5.8). Preferred time until the effect of onset was ‘up to 1 week’ for 76.2% of the patients. Most of the patients (57.9%) preferred oral administrations and the most preferred frequency of administration was ‘once per day’ (46.3%). Mean physical and mental component summary scores for Short Form 36 (V2) survey were 37.9 (±8.3) and 40.1 (±10.7).Conclusion:Two-thirds of the patients with RA who have suboptimal responses are not satisfied with their treatments. Moreover, oral and once-daily treatment approaches stand out in patient preferences. Finally, suboptimal control leads to deterioration in clinical characteristics, workability, and QoL of patients with RA.Acknowledgements:The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors have received research funding for this study. The authors wish to thank B. Murat Ozdemir of Monitor CRO for medical editing and reviewing services of this manuscript. AbbVie provided funding to Monitor CRO for this work.Disclosure of Interests:Umut Kalyoncu Speakers bureau: AbbVie, Pfizer, UCB, Novartis, and Janssen, Consultant of: AbbVie, Pfizer, UCB, Novartis, and Lilly, Grant/research support from: AbbVie, Pfizer, and Janssen, Adem Kucuk Speakers bureau: AbbVie, Gokhan Sargin: None declared, Fatih Ozdener Speakers bureau: UCB, Nutricia Advanced Medical Nutrition, Grant/research support from: Nutricia Advanced Medical Nutrition, Servet Yolbaş Speakers bureau: AbbVie, UCB, Pfizer, and MSD, Berna Yurttas: None declared, Sezin Turan: None declared, Gezmiş Kimyon Speakers bureau: AbbVie, Amgen, Pfizer, Novartis, UCB, MSD, Johnson and Johnson, and Celltrion, Consultant of: Amgen, and Pfizer, ALI SAHIN Speakers bureau: Roche, Pfizer, and AbbVie, Consultant of: Roche and Pfizer, Sedat Yilmaz Speakers bureau: UCB, Pfizer, AbbVie, MSD, Novartis, and Celltrion, Consultant of: Pfizer and Novartis, Ridvan Mercan Speakers bureau: AbbVie, Novartis, MSD, Pfizer, UCB, Roche, Amgen, and Celltrion, Consultant of: Novartis, MSD, Pfizer, and Celltrion, Hakan Emmungil Speakers bureau: AbbVie, Pfizer, Novartis, and MSD, Muhammet Çinar Speakers bureau: AbbVie, Pfizer, Celltrion, UCB, Amgen, Novartis, and MSD, Grant/research support from: AbbVie, Pfizer, Celltrion, UCB, Amgen, Novartis, and MSD, İlhan Sezer Speakers bureau: AbbVie, Pfizer, MSD, Novartis, Celltrion, UCB, Amgen, and Abdi Ibrahim, Consultant of: AbbVie, Pfizer, MSD, Novartis, Celltrion, UCB, Amgen, and Abdi Ibrahim, Grant/research support from: AbbVie, Pfizer, MSD, Novartis, Celltrion, UCB, Amgen, and Abdi Ibrahim, Timuçin Kaşifoğlu Speakers bureau: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB, Fulya Cosan Speakers bureau: AbbVie, Pfizer, Novartis, UCB, and MSD, Taskin Senturk: None declared, Nevsun Inanc Speakers bureau: AbbVie, UCB, Novartis, Pfizer, Roche, Lilly and MSD, Consultant of: Roche and Pfizer, Grant/research support from: Roche and Pfizer